2021 DAS/BAETS/ENTUK共识指南:甲状腺术后血肿的管理

2021-09-21 困难气道协会 Anaesthesia

本文主要针对甲状腺术后血肿的管理提供共识指导,内容涉及监测、术后血肿急救、疑似血脂的处理等。

中文标题:

2021 DAS/BAETS/ENTUK共识指南:甲状腺术后血肿的管理

英文标题:

Management of haematoma after thyroid surgery: systematic review and multidisciplinary consensus guidelines from the Difficult Airway Society, the British Association of Endocrine and Thyroid Surgeons and the British Association of Otorhino

发布机构:

困难气道协会

发布日期:

2021-09-21

简要介绍:

2021年9月,困难气道协会(DAS)联合英国内分泌和甲状腺外科医师协会(BAETS)、英国耳鼻咽喉头颈外科协会(ENTUK)发布了甲状腺术后血肿的管理共识指南。甲状腺术后血肿可导致气道阻塞和死亡,本文主要针对甲状腺术后血肿的管理提供共识指导,内容涉及监测、术后血肿急救、疑似血脂的处理等。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 DAS/BAETS/ENTUK共识指南:甲状腺术后血肿的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=db5ab1c00219106c, title=2021 DAS/BAETS/ENTUK共识指南:甲状腺术后血肿的管理, enTitle=Management of haematoma after thyroid surgery: systematic review and multidisciplinary consensus guidelines from the Difficult Airway Society, the British Association of Endocrine and Thyroid Surgeons and the British Association of Otorhino, guiderFrom=Anaesthesia, authorId=0, author=, summary=本文主要针对甲状腺术后血肿的管理提供共识指导,内容涉及监测、术后血肿急救、疑似血脂的处理等。, cover=https://img.medsci.cn/2021922/1632319495178_5579292.jpg, journalId=0, articlesId=null, associationId=313, associationName=困难气道协会, associationIntro=困难气道协会(DAS)是位于英国的医学专家组织,成立于1995年,现已经拥有超过2000多名会员,这些会员主要是管理病人气道的麻醉医师以及重症监护医师。协会致力于提高相关专业医师的医疗技能与水平。, copyright=0, guiderPublishedTime=Tue Sep 21 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年9月,困难气道协会(DAS)联合英国内分泌和甲状腺外科医师协会(BAETS)、英国耳鼻咽喉头颈外科协会(ENTUK)发布了甲状腺术后血肿的管理共识指南。甲状腺术后血肿可导致气道阻塞和死亡,本文主要针对甲状腺术后血肿的管理提供共识指导,内容涉及监测、术后血肿急救、疑似血脂的处理等。</span></p>, tagList=[TagDto(tagId=736, tagName=甲状腺)], categoryList=[CategoryDto(categoryId=23, categoryName=普通外科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=736, guiderKeyword=甲状腺, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4818, appHits=153, showAppHits=0, pcHits=467, showPcHits=4665, likes=1, shares=11, comments=5, approvalStatus=1, publishedTime=Wed Sep 22 22:09:16 CST 2021, publishedTimeString=2021-09-21, pcVisible=1, appVisible=1, editorId=5589422, editor=admintest, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Wed Sep 22 22:09:06 CST 2021, updatedBy=6415643, updatedName=凯晨, updatedTime=Sat Jan 06 19:02:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 DAS/BAETS/ENTUK共识指南:甲状腺术后血肿的管理.pdf)])
2021 DAS/BAETS/ENTUK共识指南:甲状腺术后血肿的管理.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1185923, encodeId=a4b91185923bf, content=ganxie, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Wed Jan 19 09:32:12 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080908, encodeId=3ad11080908ca, content=多谢大神提供指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIYL3JsTxIWlrvR1IMzXKBrhvsD7qJ17skGAgCK6Iib447Cia6yfZg6ib0icCfAficuFmdeficrt2eo0BeA/132, createdBy=96d72437514, createdName=江左梅郎, createdTime=Thu Dec 16 22:29:29 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054045, encodeId=95c81054045df, content=收益很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210323/9e19622684d0495ab64e9c2d9662c072/5dbfd70bbbc341839babfa759db3f40b.jpg, createdBy=d8d72465758, createdName=12428a36m61暂无昵称, createdTime=Thu Sep 23 08:39:51 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2022-01-19 walking

    ganxie

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1185923, encodeId=a4b91185923bf, content=ganxie, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Wed Jan 19 09:32:12 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080908, encodeId=3ad11080908ca, content=多谢大神提供指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIYL3JsTxIWlrvR1IMzXKBrhvsD7qJ17skGAgCK6Iib447Cia6yfZg6ib0icCfAficuFmdeficrt2eo0BeA/132, createdBy=96d72437514, createdName=江左梅郎, createdTime=Thu Dec 16 22:29:29 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054045, encodeId=95c81054045df, content=收益很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210323/9e19622684d0495ab64e9c2d9662c072/5dbfd70bbbc341839babfa759db3f40b.jpg, createdBy=d8d72465758, createdName=12428a36m61暂无昵称, createdTime=Thu Sep 23 08:39:51 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2021-12-16 江左梅郎

    多谢大神提供指南

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1185923, encodeId=a4b91185923bf, content=ganxie, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Wed Jan 19 09:32:12 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080908, encodeId=3ad11080908ca, content=多谢大神提供指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIYL3JsTxIWlrvR1IMzXKBrhvsD7qJ17skGAgCK6Iib447Cia6yfZg6ib0icCfAficuFmdeficrt2eo0BeA/132, createdBy=96d72437514, createdName=江左梅郎, createdTime=Thu Dec 16 22:29:29 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054045, encodeId=95c81054045df, content=收益很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210323/9e19622684d0495ab64e9c2d9662c072/5dbfd70bbbc341839babfa759db3f40b.jpg, createdBy=d8d72465758, createdName=12428a36m61暂无昵称, createdTime=Thu Sep 23 08:39:51 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2021-09-23 12428a36m61暂无昵称

    收益很多

    0

拓展阅读

2009 ATA 甲状腺结节和分化型甲状腺癌指南修订版

美国甲状腺协会(ATA,American Thyroid Association) · 2009-12-01

2010AACE/AME/ETA 欧美甲状腺结节诊断和治疗临床指南

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2010-01-01

分化型甲状腺癌诊治指南

中国抗癌协会头颈肿瘤外科专业委员会 · 2010-10-01

2011 ATA实践建议:采用放射性131碘治疗的甲状腺疾病患者的辐射安全

美国甲状腺协会(ATA,American Thyroid Association) · 2011-03-18

2011ATA/AACE《甲亢和其他病因甲状腺毒症诊治指南》

美国甲状腺协会(ATA,American Thyroid Association) · 2011-06-01

2011 中国先天性甲状腺功能减低症诊疗共识

中华医学会儿科学分会内分泌遗传代谢学组 · 2011-06-01